Contemporary Reviews in Cardiovascular Medicine Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy

Consequently, it is timely to summarize what hasbeen learned about HCM-related SD over these 5 decades,including the electrophysiological substrate, epidemiology,risk markers, and ultimately the role of ICDs, which havechanged the natural course of this complex disease.This discussion emphasizes the clarification of areas inwhich disagreement and divergent views arise, by usingavailable information to achieve a balanced assessment of SDin HCM. However, these observations ultimately representonly a “snapshot” in time for what undoubtedly will prove tobe an evolving area of investigation and understanding.

[1]  G. Giannakoulas,et al.  Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.

[2]  B. Maron,et al.  The case for myocardial ischemia in hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[3]  J. Towbin,et al.  Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. , 2009, Journal of the American College of Cardiology.

[4]  J. Hodges,et al.  Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. , 2009, Heart rhythm.

[5]  I. Palacios,et al.  Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.

[6]  D. Corrado,et al.  Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. , 2009, European heart journal.

[7]  M. Link,et al.  Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. , 2009, Heart rhythm.

[8]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[9]  C. Semsarian,et al.  Multiple Mutations in Genetic Cardiovascular Disease: A Marker of Disease Severity? , 2009, Circulation. Cardiovascular genetics.

[10]  B. Gersh,et al.  Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy , 2009, Heart.

[11]  M. Gold,et al.  Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[12]  B. Gersh,et al.  Circadian Rhythm of Appropriate Implantable Cardioverter Defibrillator Discharges in Patients with Hypertrophic Cardiomyopathy , 2008, Pacing and clinical electrophysiology : PACE.

[13]  B. Maron,et al.  Implantable Defibrillators and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[14]  A. Epstein.  Benefits of the implantable cardioverter-defibrillator. , 2008, Journal of the American College of Cardiology.

[15]  M. Josephson,et al.  A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. , 2008, Journal of the American College of Cardiology.

[16]  Warren J Manning,et al.  Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy , 2008, Circulation. Heart failure.

[17]  B. Gersh,et al.  Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2008, Circulation.

[18]  J. Bourke,et al.  Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. , 2008, European heart journal.

[19]  J. Ornato,et al.  ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2008, Heart rhythm.

[20]  J. Triedman,et al.  Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. , 2008, Journal of the American College of Cardiology.

[21]  W. Manning,et al.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[22]  B. Maron,et al.  Significance of Appropriate Defibrillator Shock 3 Hours and 20 Minutes Following Implantation in a Patient with Hypertrophic Cardiomyopathy , 2008, Journal of cardiovascular electrophysiology.

[23]  W. Roberts,et al.  Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. , 2008, The American journal of cardiology.

[24]  J. Seidman,et al.  Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics , 2007, Journal of cardiovascular electrophysiology.

[25]  C. Berul,et al.  Electrophysiological interventions for inherited arrhythmia syndromes. , 2007, Circulation.

[26]  L. Harris,et al.  Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy , 2007, Heart.

[27]  R. Passman,et al.  Sudden Death Prevention With Implantable Devices , 2007, Circulation.

[28]  S. Ommen,et al.  Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar? , 2007, JAMA.

[29]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[30]  C. Gornick,et al.  Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. , 2007, Heart rhythm.

[31]  W. Maisel,et al.  Transvenous implantable cardioverter-defibrillator leads: the weakest link. , 2007, Circulation.

[32]  B. Maron,et al.  Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy , 2007, Heart.

[33]  G. Boriani,et al.  Electrophysiologic Manifestations of Ventricular Tachyarrhythmias Provoking Appropriate Defibrillator Interventions in High‐Risk Patients with Hypertrophic Cardiomyopathy , 2007, Journal of cardiovascular electrophysiology.

[34]  A. Tajik,et al.  Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[35]  M. Link,et al.  Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2006, Circulation.

[36]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[37]  N. Lakkis,et al.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. , 2006, Journal of interventional cardiology.

[38]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[39]  A. Tajik,et al.  Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[40]  M. Gold,et al.  Sustained Ventricular Tachycardia Following Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy , 2005, Pacing and clinical electrophysiology : PACE.

[41]  Robert G. Hauser,et al.  Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator , 2005, Circulation.

[42]  M. Link,et al.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[43]  B. Maron,et al.  Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. , 2005, Heart rhythm.

[44]  B. Maron,et al.  Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. , 2005, The American journal of cardiology.

[45]  H. Kuhn,et al.  Transcoronary Ablation of Septal Hypertrophy Does Not Alter ICD Intervention Rates in High Risk Patients with Hypertrophic Obstructive Cardiomyopathy , 2005, Pacing and clinical electrophysiology : PACE.

[46]  A. Moss,et al.  Long-Term Clinical Course of Patients After Termination of Ventricular Tachyarrhythmia by an Implanted Defibrillator , 2004, Circulation.

[47]  T. Ports,et al.  Ventricular tachycardia complicating alcohol septal ablation. , 2004, The New England journal of medicine.

[48]  R. Hauser,et al.  Deaths associated with implantable cardioverter defibrillator failure and deactivation reported in the United States Food and Drug Administration Manufacturer and User Facility Device Experience Database. , 2004, Heart rhythm.

[49]  C. Semsarian,et al.  Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[50]  K. Gauvreau,et al.  Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. , 2004, The American journal of cardiology.

[51]  A. van Rossum,et al.  Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. , 2004, Journal of the American College of Cardiology.

[52]  A. Tajik,et al.  Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease , 2003, Circulation.

[53]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[54]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[55]  M. Link,et al.  Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. , 2003, Circulation.

[56]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[57]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[58]  Iacopo Olivotto,et al.  Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[59]  A. Tajik,et al.  Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. , 2002, Journal of the American College of Cardiology.

[60]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[61]  E. Behr,et al.  Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death , 2002, Heart.

[62]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[63]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[64]  A. Camm,et al.  The utilization of the implantable defibrillator--a European enigma. , 2000, European heart journal.

[65]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[66]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[67]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[68]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[69]  P. Elliott,et al.  Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[70]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. , 1999, JAMA.

[71]  Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the Cardia Study , 1996 .

[72]  B. Maron,et al.  Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. , 1995, Journal of the American College of Cardiology.

[73]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[74]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[75]  B. Maron,et al.  Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. , 1993, The American journal of cardiology.

[76]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[77]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[78]  W. Roberts,et al.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.

[79]  C. Oakley,et al.  Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. , 1985, British heart journal.

[80]  V L Gott,et al.  Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. , 1980, The New England journal of medicine.

[81]  W. Roberts,et al.  Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum of Patients with Hypertrophic Cardiomyopathy , 1979, Circulation.

[82]  C. Lambrew,et al.  Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients , 1964, Circulation.

[83]  D TEARE,et al.  ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.

[84]  J. Stockman.  Clinical Outcome and Phenotypic Expression in LAMP2 Cardiomyopathy , 2011 .

[85]  B. Maron,et al.  Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy , 2009 .

[86]  Kent R Nilsson,et al.  Early failure of a small diameter high-voltage implantable cardioverter-defibrillator lead. , 2008, Heart rhythm.

[87]  R. Bonow,et al.  36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes With Cardiovascular Abnormalities , 2005 .

[88]  U. Raute-Kreinsen.  Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. , 2003, Pathology, research and practice.

[89]  L. McLain,et al.  Sudden death in young athletes. , 2003, Pediatric annals.

[90]  W. Roberts,et al.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.